Nodes Logo
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Clarametyx Biosciences

Innovating Beyond Antibiotics to Fight Biofilm-associated Disease

| Overview |

Clarametyx is a clinical-stage biotechnology company that develops immune-enabling biologic therapies to fight life-threatening infections. Their novel adjuvant therapy disrupts biofilms, a primary mechanism for antibiotic resistance, with remarkable broad-spectrum efficacy. This wide application enables them to pursue any number of indications, and the lead product CMTX-101 is further being targeted towards cystic fibrosis and chronic infections in partnership with the Cystic Fibrosis Foundation, aiming to bring real change to a notoriously difficult condition.




Series A


Capital Raise

Transaction Value

USD 33,000,000


Cystic Fibrosis, Bacterial Infections, Pneumonia, Otitis Media, Inflammation



Cystic Fibrosis Foundation, Ohio Innovation Fund, Nationwide Children’s Hospital, Rev1 Ventures, JobsOhio Growth Capital, C Bio Investors, 1776 Fund


Charles McOsker, Ph.D., Juliana Woda, Ph.D., Michael Triplett, Ph.D., Peter G. Kleinhenz,


Serious bacterial infections is biofilm-driven

Serious bacterial infections, which are largely biofilm-driven, are driving the global threat of antimicrobial resistance. More antibiotics alone will not solve the problem.

Conventional antibiotics and innate immune effectors cannot effectively kill biofilm-residing bacteria. Biofilm-driven need for higher doses and repeated, prolonged use of antibiotics contributes to resistance. Recent WHO, Lancet and BIO reports cite major failures in antibiotic development and innovation.


A differentiated technology platform and approach with disruptive potential

Clarametyx's approach: Target the universal biofilm structure itself with therapeutics and vaccines to eliminate this defense mechanism and increase effectiveness of immune intervention and antibiotics to clear infections.

     1. Enables Rapid Immune Intervention.

     2. Dramatically Improves Susceptibility to Antibiotics.

     3. Reduces Site-Specific Inflammation to Improve Recovery.


Game-changing science

     1. Novel immune-enabling, pro-stewardship technology platform appliable to all bacterial biofilm-associated diseases.

     2. Premise derived from groundbreaking discoveries in biofilm structure.

     3. CMTX-101 therapeutic for pneumonia and cystic fibrosis complements front line antibiotics for superiority to SoC.

     4. CMTX-301 broad-spectrum vaccine for otitis media addresse.

Get in touch

Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.